Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Targeted therapies, which include monoclonal antibodies and small molecule inhibitors, have significantly changed the treatment of cancer over the past 10 years. These drugs are now a component of therapy for many common malignancies, including breast, colorectal, lung, and pancreatic cancers, as well as lymphoma, leukemia, and multiple myeloma. The mechanisms of action and toxicities of targeted therapies differ from those of traditional cytotoxic chemotherapy. Targeted therapies are generally better tolerated than traditional chemotherapy, but they are associated with several adverse effects, such as acneiform rash, cardiac dysfunction, thrombosis, hypertension, and proteinuria.
The global targeted cancer therapies market is witnessing significant growth owing to rise in incidence rate of cancer, minimal adverse effects and high adoption rate. There has been tremendous innovation over the past decade with the emergence of new drugs with very promising efficacy, along with increasing adoption of precision medicine technologies, as well as advanced monitoring techniques such as liquid biopsy. The use of targeted therapy has markedly changed outcomes for some diseases. Imatinib has had a dramatic effect on chronic myeloid leukemia, and rituximab, sunitinib, and trastuzumab have revolutionized the treatment of non-Hodgkin’s lymphoma, renal cell carcinoma, and breast cancer, respectively. Targeted therapy also introduces new economic considerations. Substituting oral small molecule inhibitors for traditional chemotherapy eliminates some treatment costs, including those associated with vascular access and intravenous infusions.
The report analyses the global targeted cancer therapies market based on type, cancer type, end user and geography.
Based on type, the market is categorized into angiogenesis inhibitors, apoptosis inducers, gene expression modulators, hormone therapies, immunotherapies, monoclonal antibodies and signal transduction inhibitors. Monoclonal antibodies exert their anticancer effects through a variety of mechanisms including; by recruiting host immune functions to attack the target cell; by binding to ligands or receptors, thereby interrupting essential cancer cell processes; or by carrying a lethal payload, such as a radioisotope or toxin, to the target cell.
By various cancer types, the global targeted cancer therapies market is segmented into breast cancer, colorectal cancer, gastrointestinal, leukemia, lung cancer, lymphoma, melanoma, prostate cancer and others. The FDA has approved targeted therapies for more than 15 types of cancer, including those of the breast, prostate, colon, and lung. Some of the products used for Breast cancer are Everolimus (Afinitor), tamoxifen (Nolvadex), toremifene (Fareston), Trastuzumab (Herceptin), fulvestrant (Faslodex), anastrozole (Arimidex), exemestane (Aromasin), lapatinib (Tykerb), letrozole (Femara), pertuzumab (Perjeta), ado-trastuzumab emtansine (Kadcyla), palbociclib (Ibrance), ribociclib (Kisqali), neratinib maleate (Nerlynx), abemaciclib (Verzenio), olaparib (Lynparza) etc.
By various end users, the global targeted cancer therapies market is segmented into hospitals, cancer & radiation therapy centers and clinics. Overall, patients prefer less invasive outpatient procedures that can be performed in doctor’s office, instead of hospital procedures that would potentially require anaesthesia.
By geography, the global targeted cancer therapies market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and rest of the world regions which includes Latin America, and Middle East & Africa. North America dominated the global targeted cancer therapies market in 2018. A combination of factors such as technology innovations, medical insurance coverage, aging population, and changing lifestyles are seen to affect market dynamics significantly. The industry has seen several recent changes including growing competition, rise in merger and acquisition activities, increased cancer health insurance coverage, and an increasing amount of foreign direct investment. Also, Asia-Pacific is anticipated to be the fastest growing region during the forecast period. This market is hugely driven by rising demand and investment level of government. In more developed region such as Japan and China, the offerings from the market players are expected to be diverse, focused mainly on customized demands. Additionally, the market is predicted to witness expansion in terms of the newer forms of drugs because of rising cancer incidence and growing awareness.
The leading market players of the global targeted cancer therapies market are Abbott Laboratories, AstraZeneca PLC, AVEO Pharmaceuticals Inc., Bayer AG, Boehringer Ingelheim GmbH, CYTOKINETICS INC., GlaxoSmithKline plc, OncoGenex Pharmaceuticals Inc., Sanofi and Pfizer, Inc. In June 2018, Bayer AG and the University of Texas MD Anderson Cancer Center signed a five-year collaboration agreement to accelerate the development of novel targeted treatments based on patient or tumor characteristics for which current therapies have not shown satisfactory clinical efficacy. Moreover, in July 2018, Sanofi and REVOLUTION Medicines, Inc. announced an exclusive partnership to develop and commercialize targeted therapies, based on the biology of the cellular enzyme SHP2, for patients with non-small lung cancer and other types of cancer carrying certain mutations.
The global targeted cancer therapies market is segmented based on type, cancer type, end user and geography. Based on type, the market is categorized into angiogenesis inhibitors, apoptosis inducers, gene expression modulators, hormone therapies, immunotherapies, monoclonal antibodies and signal transduction inhibitors.
By various cancer types, the global targeted cancer therapies market is segmented into breast cancer, colorectal cancer, gastrointestinal, leukemia, lung cancer, lymphoma, melanoma, prostate cancer and others. The FDA has approved targeted therapies for more than 15 types of cancer, including those of the breast, prostate, colon, and lung.
By various end users, the global targeted cancer therapies market is segmented into hospitals, cancer & radiation therapy centers and clinics. Overall, patients prefer less invasive outpatient procedures that can be performed in doctor’s office, instead of hospital procedures that would potentially require anaesthesia.
By geography, the global targeted cancer therapies market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and rest of the world regions which includes Latin America, and Middle East & Africa. North America dominated the global targeted cancer therapies market in 2018. A combination of factors such as technology innovations, medical insurance coverage, aging population, and changing lifestyles are seen to affect market dynamics significantly.
Why to buy this report:
